PSMB4 Antibody (monoclonal) (M01)
Mouse monoclonal antibody raised against a full length recombinant PSMB4.
- 产品详情
- 实验流程
- 背景知识
Application ![]()
| WB, IHC, E |
---|---|
Primary Accession | P28070 |
Other Accession | BC000331 |
Reactivity | Human |
Host | mouse |
Clonality | monoclonal |
Isotype | IgG1 kappa |
Clone Names | 6G7-E8 |
Calculated MW | 29204 Da |
Gene ID | 5692 |
---|---|
Other Names | Proteasome subunit beta type-4, 26 kDa prosomal protein, HsBPROS26, PROS-26, Macropain beta chain, Multicatalytic endopeptidase complex beta chain, Proteasome beta chain, Proteasome chain 3, HsN3, PSMB4, PROS26 |
Target/Specificity | PSMB4 (AAH00331, 1 a.a. ~ 264 a.a) full-length recombinant protein with GST tag. MW of the GST tag alone is 26 KDa. |
Dilution | WB~~1:500~1000 IHC~~1:100~500 E~~N/A |
Format | Clear, colorless solution in phosphate buffered saline, pH 7.2 . |
Storage | Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing. |
Precautions | PSMB4 Antibody (monoclonal) (M01) is for research use only and not for use in diagnostic or therapeutic procedures. |
For Research Use Only. Not For Use In Diagnostic Procedures.
Provided below are standard protocols that you may find useful for product applications.
BACKGROUND
The proteasome is a multicatalytic proteinase complex with a highly ordered ring-shaped 20S core structure. The core structure is composed of 4 rings of 28 non-identical subunits; 2 rings are composed of 7 alpha subunits and 2 rings are composed of 7 beta subunits. Proteasomes are distributed throughout eukaryotic cells at a high concentration and cleave peptides in an ATP/ubiquitin-dependent process in a non-lysosomal pathway. An essential function of a modified proteasome, the immunoproteasome, is the processing of class I MHC peptides. This gene encodes a member of the proteasome B-type family, also known as the T1B family, that is a 20S core beta subunit. [provided by RefSeq]
REFERENCES
1.Predictive value of PAK6 and PSMB4 expression in patients with localized prostate cancer treated with dose-escalation radiation therapy and androgen deprivation therapy.Zapatero A, Morente M, Nieto S, Mart?n de Vidales C, Lopez C, Adrados M, Arellano R, Artiga MJ, Garcia-Vicente F, Herranz LM, Leaman O.Urol Oncol. 2014 Jun 16. pii: S1078-1439(14)00167-7.

终于等到您。ABCEPTA(百远生物)抗体产品。
点击下方“我要评价 ”按钮提交您的反馈信息,您的反馈和评价是我们最宝贵的财富之一,
我们将在1-3个工作日内处理您的反馈信息。
如有疑问,联系:0512-88856768 tech-china@abcepta.com.